Classen Immunotherapies' Peer Reviewed Data Suggests the Measles/Mumps/Rubella Vaccine Protects Against COVID-19, Additional Studies in Progress
BALTIMORE - 05/19/2020 — Classen Immunotherapies Inc. has just published in the peer reviewed journal Diabetes & its Complications evidence that the measles/mumps/rubella vaccine may provide protection against infections with COVID-19. Non peer reviewed data from several other groups support this finding. These findings are not meant to be a clinical recommendation.
US military has stated that the COVID-19 pandemic may be an bioweapon attack. Several respected scientist have claimed that the genome of COVID-19 actually supports that the virus is man made. In the current publication the author explores the possibility that the COVID-19 pandemic may be a bioweapon attack. “The first step to resolve the pandemic must be to determine if the COVID-19 pandemic is a biological weapons attack” Classen states.
To learn more about the research of immunologist J. Bart Classen, MD see the website http://www.vaccines.net
For further information contact classen@vaccines.net
Media Contacts:
Company Name: Classen Immunotherapies, IncFull Name: . Bart Classen, MD
Email Address: Send Email
Website: http://www.vaccines.net/